Hunter Eagle
liked
Today is Wednesday. March 19th. This afternoon, for the first time since January 29th, or for the second time this year, the Federal Reserve's FOMC (Federal Open Market Committee) will release an official statement on monetary policy. Happy Fed Day to all who celebrate. The festivities begin at 14:00 ET. That's when the above-mentioned statement (eight times a year) will be released alongside the committee's quarterly (first release for 2025) economic projections. A half hour later, Fed C...
13
Hunter Eagle
liked
3
2
Hunter Eagle
liked
A big day today, J Powow speaks, and the dots get plotted 😆
I will start with QQQ/ND and VIX, and then I will move to individual stocks. I don't own these and don't necessarily recommend buying them. I use them as sentiment and market bias/direction indicators.
I will be upfront and say my bias is up. How high doesn't really matter to me. I don't own the MAG 7. I just want to see willing buyers. I'm not nieve and am hedged for downside. but I have been buying a lot of individual ...
I will start with QQQ/ND and VIX, and then I will move to individual stocks. I don't own these and don't necessarily recommend buying them. I use them as sentiment and market bias/direction indicators.
I will be upfront and say my bias is up. How high doesn't really matter to me. I don't own the MAG 7. I just want to see willing buyers. I'm not nieve and am hedged for downside. but I have been buying a lot of individual ...
+33
35
3
2
Hunter Eagle
liked
$GAMUDA (5398.MY)$ Today Gamuda opened at 4.07 moved up swiftly to 4.22 breaking decisively 4.12, its medium term support turned resistance on its way up .It then pulled back to test 4.05, its 200 days support before closing at 4.08 managed a 4 sen gain.
Tomorrow will see it attempting to break 4.23 its 150day MA , then retest 4.26 ,its 20 day MA. Once it is done , 4.50 overhead will be the next high to challenge.Failing which the immediate support will be 3.75 , its 250 day MA .
Strictly an ...
Tomorrow will see it attempting to break 4.23 its 150day MA , then retest 4.26 ,its 20 day MA. Once it is done , 4.50 overhead will be the next high to challenge.Failing which the immediate support will be 3.75 , its 250 day MA .
Strictly an ...
6
Hunter Eagle
liked
$Allarity Therapeutics (ALLR.US)$ Why is there a Bullish outlook on $ALLR?
1) A solid scientific foundation
The clinical data of Allarity ($ALLR) is convincing! They utilize a precision oncology strategy with the PARP inhibitor Stenoparib targeting the WNT pathway, demonstrating astonishing potential. Their Phase II clinical trial was prematurely terminated due to significant efficacy—one patient achieved complete remission, while several others experienced significantly extended survival times. It is important to note that Stenoparib is mainly used as a last resort after all treatment options have failed, and such results are truly remarkable!
2) Market concerns: The issues of share issuance & reverse stock splits have eased.
Investors previously had concerns about share issuance and reverse stock splits, but the situation has now improved:
✅ CEO Thomas Jensen has explicitly committed to avoiding 'toxic financing' and will focus on enhancing Shareholder value.
The company has officially canceled the S-1 registration statement, significantly reducing the potential risk of dilution.
Currently, there is only about 10 million USD remaining in ATM financing (by my calculations), but considering the company's recent announcement of a 5 million USD Share Buyback, it is highly unlikely to be utilized. (The SEC generally does not encourage companies to engage in ATM financing while simultaneously repurchasing stocks.)
Currently, there is only one category of Stocks, and there are no impacts from debt conversions or warrants.
Regarding legal/regulatory issues.
In the past, Allarity faced challenges due to the mistakes of the previous management.
1) A solid scientific foundation
The clinical data of Allarity ($ALLR) is convincing! They utilize a precision oncology strategy with the PARP inhibitor Stenoparib targeting the WNT pathway, demonstrating astonishing potential. Their Phase II clinical trial was prematurely terminated due to significant efficacy—one patient achieved complete remission, while several others experienced significantly extended survival times. It is important to note that Stenoparib is mainly used as a last resort after all treatment options have failed, and such results are truly remarkable!
2) Market concerns: The issues of share issuance & reverse stock splits have eased.
Investors previously had concerns about share issuance and reverse stock splits, but the situation has now improved:
✅ CEO Thomas Jensen has explicitly committed to avoiding 'toxic financing' and will focus on enhancing Shareholder value.
The company has officially canceled the S-1 registration statement, significantly reducing the potential risk of dilution.
Currently, there is only about 10 million USD remaining in ATM financing (by my calculations), but considering the company's recent announcement of a 5 million USD Share Buyback, it is highly unlikely to be utilized. (The SEC generally does not encourage companies to engage in ATM financing while simultaneously repurchasing stocks.)
Currently, there is only one category of Stocks, and there are no impacts from debt conversions or warrants.
Regarding legal/regulatory issues.
In the past, Allarity faced challenges due to the mistakes of the previous management.
Translated
6
Hunter Eagle
liked
![[empty]](https://static.moomoo.com/node_futunn_nnq/assets/images/folder.5c37692712.png)
![[error]](https://static.moomoo.com/node_futunn_nnq/assets/images/no-network.991ae8055c.png)
![[loading]](data:image/svg+xml;base64,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)